• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

X-Biotix to address antibiotic resistance with chemical scaffolds

May 30, 2017 By Sarah Faulkner

X-Chem PharmaceuticalsX-Biotix Therapeutics launched today with technology from Harvard Medical School that the company said will aim to address the threat of antibiotic resistance.

According to the multi-year collaboration and license agreement, the team plans to identify antibiotic scaffolds that target multi-drug-resistant Gram-negative pathogens.

X-Biotix spun out of the privately-held biotech X-Chem, which develops novel small molecule therapeutics using its DNA-encoding technology platform, DEX. X-Biotix plans to use the DEX platform to discover and develop chemical scaffolds that target Gram-negative pathogens.

The company also has access to assays for promising compounds from the X-Chem libraries, according to the license agreement with Harvard.

“I am excited about the application of X-Chem’s innovative and proprietary platform, which includes ‘antibiotic-like’ chemistry and ‘natural product-like’ chemical space to support our efforts in establishing a pipeline and advancing the development of novel antibiotic therapies,” X-Biotix CEO Ramani Varanasi said in prepared remarks. “The multi-target discovery strategy enabled by our foundational collaboration with researchers at HMS, combined with the screening of the ultra-large and diverse chemical space, uniquely positions X-Biotix to address the critical global challenge of resistance to antibiotics.”

“Recent advances in understanding the pathways that bacteria use to build critical components of their cells have revealed novel vulnerabilities ready to exploit for antibiotic discovery,” John Mekalanos added. Mekalanos is a professor of microbiology & immunobiology at Harvard, as well as a co-founder and chair of X-Biotix’s scientific advisory board. “It is exciting to embark on this new collaborative investigation that seeks novel solutions to the serious problem of antibiotic drug resistance.”

Multi-drug-resistant pathogens infect millions of people annually, according to the company, and the need for novel antibacterial therapies is expected to grow in the coming years.

“The formation of X-Biotix comes at a critical time in the industry, where the general void in antibiotic discovery efforts combined with the lack of specific efforts to discover and develop truly novel chemical scaffolds represents a challenge waiting to be addressed using a unique discovery approach,” X-Chem CEO Rick Wagner said.

Filed Under: Featured, Pharmaceuticals, Research & Development Tagged With: Harvard University, xbiotixtherapeutics

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS